Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 151-158

  Sudchada, Patcharaporn ^a   Saokaew, Surasak ^a,b,c,d   Sridetch, Sorattaya ^a   Incampa, Siriwan ^a   Jaiyen, Sopida ^a   Khaithong, Warangkana ^a  

^a NARESUAN UNIVERSITY   (Thailand)

^b UNIVERSITY OF PHAYAO   (Thailand)

^c UNIVERSITY OF UTAH   (United States)

^d Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Diabetes; Folic acid; HbA1c; Homocysteine; Supplementary

Indexed keywords

FOLIC ACID; HEMOGLOBIN A1C; HOMOCYSTEINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; SYSTEMATIC REVIEW;

AGED; BLOOD GLUCOSE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84867402014     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.05.027     Document Type: Article

References (57)

1. Tunstall-Pedoe H., Woodward M., Tavendale R., A'Brook R., McCluskey M.K. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997, 315(September (7110)):722-729.
2. Stengard J.H., Tuomilehto J., Pekkanen J., Kivinen P., Kaarsalo E., Nissinen A., et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 1992, 35(August (8)):760-765.
3. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100(September (10)):1134-1146.
4. Chokrungvaranon N., Deer J., Reaven P.D. Intensive glycemic control and cardiovascular disease: are there patients who may benefit?. Postgrad Med 2011, 123(November (6)):114-123.
5. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995, 346(November (8987)):1395-1398.
6. Verhoef P., Hennekens C.H., Malinow M.R., Kok F.J., Willett W.C., Stampfer M.J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994, 25(October (10)):1924-1930.
7. Coull B.M., Malinow M.R., Beamer N., Sexton G., Nordt F., de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990, 21(April (4)):572-576.
8. Malinow M.R., Nieto F.J., Szklo M., Chambless L.E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993, 87(April (4)):1107-1113.
9. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995, 332(February (5)):286-291.
10. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995, 24(August (4)):704-709.
11. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268(August (7)):877-881.
12. Genest J.J., McNamara J.R., Salem D.N., Wilson P.W., Schaefer E.J., Malinow M.R. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990, 16(November (5)):1114-1119.
13. Garofolo L., Barros N., Miranda F., D'Almeida V., Cardien L.C., Ferreira S.R. Association of increased levels of homocysteine and peripheral arterial disease in a Japanese-Brazilian population. Eur J Vasc Endovasc Surg 2007, 34(July (1)):23-28.
14. Smulders Y.M., Rakic M., Slaats E.H., Treskes M., Sijbrands E.J., Odekerken D.A., et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22(January (1)):125-132.
15. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18(January (1)):133-138.
16. Stehouwer C.D., Gall M.A., Hougaard P., Jakobs C., Parving H.H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999, 55(January (1)):308-314.
17. Kark J.D., Selhub J., Bostom A., Adler B., Rosenberg I.H. Plasma homocysteine and all-cause mortality in diabetes. Lancet 1999, 353(June (9168)):1936-1937.
18. Hoogeveen E.K., Kostense P.J., Jakobs C., Dekker J.M., Nijpels G., Heine R.J., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101(April (13)):1506-1511.
19. Soinio M., Marniemi J., Laakso M., Lehto S., Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004, 140(January (2)):94-100.
20. Ndrepepa G., Kastrati A., Braun S., Koch W., Kolling K., Mehilli J., et al. A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clin Chim Acta 2006, 373(November (1-2)):70-76.
21. de Luis D.A., Fernandez N., Arranz M., Aller R., Izaola O. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res Clin Pract 2002, 55(March (3)):185-190.
22. Ambrosch A., Dierkes J., Lobmann R., Kuhne W., Konig W., Luley C., et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet Med 2001, 18(March (3)):185-192.
23. Gonzalez R., Pedro T., Real J.T., Martinez-Hervas S., Abellan M.R., Lorente R., et al. Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26(February (2)):115-120.
24. Thambyrajah J., Landray M.J., Jones H.J., McGlynn F.J., Wheeler D.C., Townend J.N. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 2001, 37(June (7)):1858-1863.
25. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52(June (6)):377-384.
26. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(February (1)):1-12.
27. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(September (3)):177-188.
28. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(June (11)):1539-1558.
29. Gargari B.P., Aghamohammadi V., Aliasgharzadeh A. Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes. Diabetes Res Clin Pract 2011, 94(1):33-38.
30. Aghamohammadi V., Gargari B.P., Aliasgharzadeh A. Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 diabetes mellitus. J Am Coll Nutr 2011, 30(June (3)):210-215.
31. Mangoni A.A., Sherwood R.A., Asonganyi B., Swift C.G., Thomas S., Jackson S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005, 18(February (2 Pt 1)):220-226.
32. Spoelstra-de M.A., Brouwer C.B., Terheggen F., Bollen J.M., Stehouwer C.D., Smulders Y.M. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Neth J Med 2004, 62(July-August (7)):246-253.
33. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(November (7374)):1202.
34. Stehouwer C.D.A., Schaper N. Therapeutic strategies in diabetes 2009, Clinical Publishing Services.
35. Ndrepepa G., Kastrati A., Braun S., Koch W., Kolling K., Mehilli J., et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008, 18(January (1)):66-73.
36. Bazzano L.A., Reynolds K., Holder K.N., He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006, 296(December (22)):2720-2726.
37. Ebbing M., Bleie O., Ueland P.M., Nordrehaug J.E., Nilsen D.W., Vollset S.E., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008, 300(August (7)):795-804.
38. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354(April (15)):1567-1577.
39. Galan P., Kesse-Guyot E., Czernichow S., Briancon S., Blacher J., Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 341:c6273.
40. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010, 9(September (9)):855-865.
41. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291(February (5)):565-575.
42. Spence J.D. Homocysteine-lowering therapy: a role in stroke prevention?. Lancet Neurol 2007, 6(September (9)):830-838.
43. Refsum H., Smith A.D. Homocysteine, B vitamins, and cardiovascular disease. N Engl J Med 2006, 355(July (2)):207-211.
44. McNulty H., Pentieva K., Hoey L., Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc 2008, 67(May (2)):232-237.
45. Carlsen S.M., Folling I., Grill V., Bjerve K.S., Schneede J., Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997, 57(October (6)):521-527.
46. Wulffele M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Borger van der Burg B., et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003, 254(November (5)):455-463.
47. Diabetes drug interferes with vitamin B12. Harv Heart Lett 2010, 20(May (9)):7.
48. Mahajan R., Gupta K. Revisiting metformin: annual vitamin b12 supplementation may become mandatory with long-term metformin use. J Young Pharm 2010, 2(October (4)):428-429.
49. Moreno H., Croce N., Kuffaty J., Chuki E., Berbesi M., Fragachan F. Therapeutical effects of folic acid on serum homocysteine in hypertensive patients. Am J Hypertens 2002, 15(114A-115A):234.
50. Ellison J., Clark P., Walker I.D., Greer I.A. Effect of supplementation with folic acid throughout pregnancy on plasma homocysteine concentration. Thromb Res 2004, 114(1):25-27.
51. Cafolla A., Dragoni F., Girelli G., Tosti M.E., Costante A., De Luca A.M., et al. Effect of folic acid and vitamin C supplementation on folate status and homocysteine level: a randomised controlled trial in Italian smoker-blood donors. Atherosclerosis 2002, 163(July (1)):105-111.
52. Vogel T., Dali-Youcef N., Kaltenbach G., Andres E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 2009, 63(July (7)):1061-1067.
53. Carmel R., Green R., Rosenblatt D.S., Watkins D. Update on cobalamin, folate, and homocysteine. Hematology Am Soc Hematol Educ Program 2003, 62-81.
54. Drion I. B-vitamin therapy for diabetic nephropathy. JAMA 2010, 304(August (6)):636. [author reply-7].
55. Spence J.D., Bang H., Chambless L.E., Stampfer M.J. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005, 36(November (11)):2404-2409.
56. House A.A., Eliasziw M., Cattran D.C., Churchill D.N., Oliver M.J., Fine A., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010, 303(April (16)):1603-1609.
57. Spence J.D., Stampfer M.J. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 2011, 306(December (23)):2610-2611.